EMAIL THIS PAGE TO A FRIEND

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Prilling as manufacturing technique for multiparticulate lipid/PEG fixed-dose combinations.


PMID 25010389

Abstract

This study focused on the evaluation of prilling as a technique for the manufacturing of multiparticulate dosage forms. Prills, providing controlled and immediate drug release, were processed and finally combined in capsules yielding a fixed-dose combination. Metoprolol tartrate (MPT) and hydrochlorothiazide (HCT) were used as controlled and immediate release model drugs, respectively. These drugs were embedded in matrices composed of fatty acids and polyethylene glycol (PEG). In order to tailor drug release from the prills, the type of fatty acid, the PEG molecular weight and the fatty acid/PEG ratio were varied. To provide controlled drug release, MPT was embedded in matrices containing PEG and behenic acid. Using different PEG molecular weights (PEG 4000, 6000 and 10,000), MPT release could be tailored over a wide range. To obtain immediate release, HCT was incorporated in matrices composed of PEG and stearic acid. Since high amounts (at least 60%) of PEG were needed for acceptable immediate release, HCT release was independent on PEG molecular weight. Solid state characterization revealed that MPT crystallinity was decreased, while HCT was molecularly dispersed throughout the matrix. Drug release of both MPT and HCT prills was stable during storage. Compared to a fixed-dose reference, oral co-administration of the MPT and HCT prills to dogs yielded a similar bioavailability for the HCT prills, while the MPT prills resulted in a significant higher bioavailability.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
H1200000
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
1314009
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
C7H8ClN3O4S2
PHR1032
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8ClN3O4S2
Y0001494
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
77402
Melting Point Standard 69-71°C, analytical standard
C18H36O2
1441298
Metoprolol succinate, United States Pharmacopeia (USP) Reference Standard
C30H50N2O6 · C4H6O4
449148
Potassium fluoride, anhydrous, powder, ≥99.9% trace metals basis
FK
229814
Potassium fluoride, ≥99.97% trace metals basis
FK
60238
Potassium fluoride, BioUltra, ≥99.5% (F)
FK
262552
Potassium fluoride on Celite®, extent of labeling: 50 wt. % loading, technical grade
FK
S4751
Stearic acid, Grade I, ≥98.5% (capillary GC)
C18H36O2
76137
Stearic acid, certified reference material, TraceCERT®
C18H36O2
85679
Stearic acid, analytical standard
C18H36O2
85680
Stearic acid, puriss., ≥98.5% (GC)
C18H36O2
W303518
Stearic acid, ≥95%, FCC, FG
C18H36O2
175366
Stearic acid, reagent grade, 95%
C18H36O2
1621008
Stearic acid, United States Pharmacopeia (USP) Reference Standard
C18H36O2
S1340000
Stearic acid, European Pharmacopoeia (EP) Reference Standard
C18H36O2
PHR1114
Stearic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
C18H36O2